DL-threo-PDMP hydrochloride
Based on 1 Customer Validation
DL-threo-PDMP hydrochloride is a competitive glucosylceramide synthase (GCS) inhibitor and antimalarial agent. DL-threo-PDMP hydrochloride competitively inhibits the activity of GCS. DL-threo-PDMP hydrochloride restores cisplatin sensitivity in cisplatin-resistant testicular germ cell tumor cells. DL-threo-PDMP hydrochloride blocks the growth of ring-stage Plasmodium falciparum parasites.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.40%
- CAS No.: 80938-69-8
- Formule: C23H39ClN2O3
- Masse moléculaire:427.02
-
Stockage:
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-K0010
Protease Inhibitor Cocktail (EDTA-Free, 100× in DMSO) -
HY-16743
IbiglustatGlucosylceramide Synthase Inhibitor -
HY-17020
MiglustatCeramide Glucosyltransferase Inhibitor -
HY-17020A
Miglustat hydrochlorideGlucosylceramide Synthase Inhibitor -
HY-116392F
D-threo-PDMP hydrochlorideGCS Inhibitor -
HY-16743A
Ibiglustat (L-Malic acid)Glucosylceramide Synthase Inhibitor -
HY-N0650S
L-Serine-13C3Stable Isotope -
HY-116392D
PDMP hydrochlorideGCS Inhibitor -
HY-N0650S11
L-Serine-d7Stable Isotope -
HY-17020R
Miglustat (Standard)Ceramide Glucosyltransferase Inhibitor -
HY-106392
LucerastatGlucosylceramide Synthase Inhibitor -
HY-144267
Glucosylceramide synthase-IN-2GCS Inhibitor
Voir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
Description
IC50 & Target
[1]|
Plasmodium |
In Vitro
DL-threo-PDMP (30 μmol/L; 48 h) hydrochloride restores cisplatin sensitivity in cisplatin-resistant SuSaR testicular germ cell tumor cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
-
Cell Line:SuSaR (cisplatin-resistant human nonseminomatous testicular germ cell teratocarcinoma cell line)
-
Concentration:30 μmol/L (combined with cisplatin treatment)
-
Incubation Time:48 h (combined with cisplatin treatment)
-
Result:Reduced the cisplatin IC50 in SuSaR cells from 2.72 ± 0.16 μg/mL to 1.22 ± 0.22 μg/mL, resulting in 44.8% cisplatin resensitization.
Significantly increased intracellular ceramide levels in SuSaR cells compared to control, cisplatin alone, or DL-threo-PDMP alone.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:50 mg/kg (single agent; combined with cisplatin 3.5 mg/kg)
-
Administration:i.p.; daily; 21 days; 1 hour before cisplatin (i.v.; once weekly; 3 consecutive weeks) for combined group
-
Result:Did not produce a significant reduction in tumor weight compared to vehicle-treated animals as a single agent.
Produced significant tumor weight reductions of 42.8% in TGT1XR tumors and 73.5% in TGT38XR tumors compared to vehicle controls when combined with cisplatin.
Induced a 2.7-fold increase in apoptotic cells (caspase-3 positive) in TGT1XR tumors and a 2.81-fold increase in TGT38XR tumors compared to cisplatin-only treatment when combined with cisplatin.
Chemical Information
-
CAS No. 80938-69-8
-
Appearance Solid
-
Masse moléculaire 427.02
-
Formule C23H39ClN2O3
-
Color White to off-white
-
SMILES
O[C@H](C1=CC=CC=C1)[C@H](NC(CCCCCCCCC)=O)CN2CCOCC2.Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (234.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Piulats JM, et al. Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent. Clin Cancer Res. 2018;24(15):3755-3766. [Content Brief]
[2]. Lauer SA, et al. Sphingolipid synthesis as a target for chemotherapy against malaria parasites. Proc Natl Acad Sci U S A. 1995;92(20):9181-9185. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3418 mL | 11.7091 mL | 23.4181 mL | 58.5453 mL |
| 5 mM | 0.4684 mL | 2.3418 mL | 4.6836 mL | 11.7091 mL | |
| 10 mM | 0.2342 mL | 1.1709 mL | 2.3418 mL | 5.8545 mL | |
| 15 mM | 0.1561 mL | 0.7806 mL | 1.5612 mL | 3.9030 mL | |
| 20 mM | 0.1171 mL | 0.5855 mL | 1.1709 mL | 2.9273 mL | |
| 25 mM | 0.0937 mL | 0.4684 mL | 0.9367 mL | 2.3418 mL | |
| 30 mM | 0.0781 mL | 0.3903 mL | 0.7806 mL | 1.9515 mL | |
| 40 mM | 0.0585 mL | 0.2927 mL | 0.5855 mL | 1.4636 mL | |
| 50 mM | 0.0468 mL | 0.2342 mL | 0.4684 mL | 1.1709 mL | |
| 60 mM | 0.0390 mL | 0.1952 mL | 0.3903 mL | 0.9758 mL | |
| 80 mM | 0.0293 mL | 0.1464 mL | 0.2927 mL | 0.7318 mL | |
| 100 mM | 0.0234 mL | 0.1171 mL | 0.2342 mL | 0.5855 mL |
DL-threo-PDMP hydrochloride Related Classifications
HY-116392B Related Classifications
Powered by Bioz
Keywords
- DL-threo-PDMP
- 80938-69-8
- Glucosylceramide Synthase (GCS)
- Parasite
- cisplatin
- tubovesicular membrane network
- glucosylceramide synthase
- epithelial ovarian cancer
- sphingomyelin synthase
- nonseminomatous testicular germ cell tumors
- Plasmodium falciparum-infected erythrocytes
- cisplatin-resistant germline-derived orthoxenografts
- malaria
- Plasmodium falciparum ring-stage parasites
- Inhibitor
- inhibitor
- inhibit